A New York Times article on the real benefits (or lack thereof) of statins, the often-prescribed drugs used to lower cholesterol and the risk for heart attacks, quoted Mark H. Ebell, a part-time professor in the Office of the Senior Vice President for Academic Affairs.
“High-risk groups have a lot to gain (from statins),” said Ebell, who also is deputy editor of the journal American Family Physician. “But patients at low risk benefit very little if at all. We end up overtreating a lot of patients.”
